NextCure Reports Initiation of NC410 + Keytruda in P-Ib/II Clinical Trial for Immune Checkpoint Refractory or Naïve Solid Tumors
Shots:
- The P-Ib/II trial evaluates NC410 + Keytruda in ~100 patients with immune checkpoint refractory colorectal, esophageal, endometrial & HNC or immune checkpoint naïve MSS or MSI-low colorectal or ovarian cancers. The initial P-Ib results are expected in mid-2023, followed by the initiation of the P-II component of the study
- NextCure will be a sponsor of the study & Merck will supply Keytruda. The combination therapy will address the unmet needs of cancer patients
- In non-clinical colorectal models & early-stage monothx. clinical studies, NC410 can remodel collagen in ECM to enhance T cell infiltration into the tumor. NC410 inhibits the negative effects of LAIR-1 & enhances T cell function and myeloid cell activity in preclinical studies
Ref: GlobeNewswire | Image: NextCure
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
